Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro

Cell and Tissue Research

Volumn 340, Issue 2, 2010, Pages 371-379

  Lawnicka, Hanna ^a   Kowalewicz Kulbat, Magdalena ^b   Sicinska, Paulina ^b   Kazimierczuk, Zygmunt ^c   Grieb, Pawel ^c   Stepien, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

2 Dimethylamino 4,5,6,7 tetrabromobenzimidazole (DMAT); Adrenocortical cancer; Caseine kinase 2; H295R cell line (Human)

Indexed keywords

2 DIMETHYLAMINO 4,5,6,7 TETRABROMOBENZIMIDAZOLE; ANTINEOPLASTIC AGENT; CASEIN KINASE II; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL CORTEX HORMONES; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ALDOSTERONE; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CASEIN KINASE II; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEHYDROEPIANDROSTERONE SULFATE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROCORTISONE; PROTEIN KINASE INHIBITORS;

EID: 77953229921     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00441-010-0960-1     Document Type: Article

References (46)

1. G Abiven J Coste L Groussin P Anract F Tissier P Legmann B Dousset X Bertagna J Bertherat 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients J Clin Endocrinol Metab 91 2650 2655 10.1210/jc.2005-2730 1:CAS:528:DC%2BD28XntFWgtL0%3D 16670169 (Pubitemid 44024632)
2. H Ahlman A Khorram-Manesh S Jansson B Wängberg O Nilsson CE Jacobsson S Lindstedt 2001 Cytotoxic treatment of adrenocortical carcinoma World J Surg 25 927 933 10.1007/s00268-001-0031-6 1:STN:280:DC%2BD3MrisVGitg%3D%3D 11572034 (Pubitemid 32666395)
3. KA Ahmad G Wang J Slaton G Unger K Ahmed 2005 Targeting CK2 for cancer therapy Anticancer Drugs 16 1037 1043 10.1097/00001813-200511000-00001 1:CAS:528:DC%2BD2MXhtV2ktrnI 16222144 (Pubitemid 41565768)
4. KA Ahmad G Wang G Unger J Slaton K Ahmed 2008 Protein kinase CK2-a key suppressor of apoptosis Adv Enzyme Regul 48 179 187 10.1016/j.advenzreg.2008.04. 002 1:CAS:528:DC%2BD1MXhsFGmtbrI 18492491
5. K Ahmed DA Gerber C Cochet 2002 Joining the cell survival squad: an emerging role for protein kinase CK2 Trends Cell Biol 12 226 230 10.1016/S0962-8924(02)02279-1 1:CAS:528:DC%2BD38XjtVehsrc%3D 12062170 (Pubitemid 34327615)
6. C Butler WM Butler AA Rizvi 2009 Sustained remission with the kinase inhibitor sorafenib in Stage IV metastatic adrenocortical carcinoma Endocr Pract 26 1 19
7. A Berruti M Terzolo P Sperone A Pia SD Casa DJ Gross C Carnaghi P Casali F Porpiglia F Mantero G Reimondo A Angeli L Dogliotti 2005 Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer 12 657 666 10.1677/erc.1.01025 1:CAS:528:DC%2BD2MXht1SjsrrN 16172198 (Pubitemid 41482999)
8. Cozza G, Bortolato A, Moro S (2009) How druggable is protein kinase CK2? Med Res Rev (in press) doi: 10.1002/med.20164)
9. F Crucitti R Bellantone A Ferrante M Boscherini P Crucitti 1996 The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group Surgery 119 161 170 10.1016/S0039-6060(96)80164-4 1:STN:280:DyaK287msFCltg%3D%3D 8571201 (Pubitemid 26052933)
10. G Di Maira F Brustolon J Bertacchini K Tosoni S Marmiroli LA Pinna M Ruzzene 2007 Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level Oncogene 26 6915 6926 10.1038/sj.onc.1210495 17486073 (Pubitemid 47609076)
11. G Di Maira F Brustolon K Tosoni S Belli SD Krämer LA Pinna M Ruzzene 2008 Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis Mol Cell Biochem 316 155 161 10.1007/s11010-008-9813-6 18560764
12. JS Duncan DW Litchfield 2008 Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2 Biochim Biophys Acta 1784 33 47 1:CAS:528:DC%2BD1cXptlCjsg%3D%3D 17931986
13. M Fassnacht B Allolio 2009 Clinical management of adrenocortical carcinoma Best Pract Res Clin Endocrinol Metab 23 273 289 10.1016/j.beem.2008. 10.008 1:CAS:528:DC%2BD1MXmvFCkur0%3D 19500769
14. M Fassnacht MC Kreissl D Weismann B Allolio 2009 New targets and therapeutic approaches for endocrine malignancies Pharmacol Ther 123 117 141 10.1016/j.pharmthera.2009.03.013 1:CAS:528:DC%2BD1MXms1ahsLY%3D 19374919
15. M Faust M Montenarh 2000 Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res 301 329 340 10.1007/s004410000256 1:CAS:528:DC%2BD3cXmvV2itbk%3D 10994779
16. SD Flynn JR Murren WM Kirby J Honig L Kan BK Kinder 1992 P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma Surgery 112 981 986 1:STN:280:DyaK3s%2FovVWktg%3D%3D 1360713
17. S Gaujoux F Tissier L Groussin R Libé B Ragazzon P Launay A Audebourg B Dousset X Bertagna J Bertherat 2008 Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors J Clin Endocrinol Metab 93 4135 4140 10.1210/jc.2008-0631 1:CAS:528:DC%2BD1cXht1GmurjM 18647815
18. D Gerlier N Thomasset 1986 Use of MTT colorimetric assay to measure cell activation J Immunol Methods 94 57 63 10.1016/0022-1759(86)90215-2 1:CAS:528:DyaL2sXjtFShsQ%3D%3D 3782817 (Pubitemid 17186343)
19. RD Gietz KC Graham DW Litchfield 1995 Interactions between the subunits of casein kinase II J Biol Chem 270 13017 13021 10.1074/jbc.270.22.13017 1:CAS:528:DyaK2MXmtV2it7g%3D 7768894
20. KC Graham DW Litchfield 2000 The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexes J Biol Chem 275 5003 5010 10.1074/jbc.275.7.5003 1:CAS:528:DC%2BD3cXhsVymsLc%3D 10671540 (Pubitemid 30108897)
21. B Guerra OG Issinger 1999 Protein kinase CK2 and its role in cellular proliferation, development and pathology Electrophoresis 20 391 408 10.1002/(SICI)1522-2683(19990201)20:2<391:AID-ELPS391>3.0.CO;2-N 1:CAS:528:DyaK1MXit1antr8%3D 10197447
22. C Guo S Yu AT Davis H Wang JE Green K Ahmed 2001 A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells J Biol Chem 276 5992 5999 10.1074/jbc.M004862200 1:CAS:528:DC%2BD3MXhs1Kmurw%3D 11069898
23. J Heil G Reifferscheid 1992 Detection of mammalian carcinogens with an immunological DNA synthesis-inhibition test Carcinogenesis 13 2389 2394 10.1093/carcin/13.12.2389 1:CAS:528:DyaK3sXnsVylsg%3D%3D 1473248
24. K Izeradjene L Douglas A Delaney JA Houghton 2005 Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines Oncogene 24 2050 2058 10.1038/sj.onc.1208397 1:CAS:528:DC%2BD2MXitlCmsro%3D 15688023 (Pubitemid 40516198)
25. TS Khan H Imam C Juhlin B Skogseid S Grondal S Tibblin E Wilander K Oberg B Eriksson 2000 Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use Ann Oncol 11 1281 1287 10.1023/A:1008377915129 1:STN:280:DC%2BD3MzgsVKltw%3D%3D 11106117
26. JS Kim JI Eom JW Cheong AJ Choi JK Lee WI Yang YH Min 2007 Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia Clin Cancer Res 13 1019 1028 10.1158/1078-0432.CCR-06- 1602 1:CAS:528:DC%2BD2sXhsVyku7c%3D 17289898 (Pubitemid 46340381)
27. LS Kirschner 2006 Emerging treatment strategies for adrenocortical carcinoma: a new hope J Clin Endocrinol Metab 91 14 21 10.1210/jc.2005-1739 1:CAS:528:DC%2BD28Xms1aitw%3D%3D 16234301 (Pubitemid 43069108)
28. M Laramas D Pasquier O Filhol F Ringeisen JL Descotes C Cochet 2007 Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer Eur J Cancer 43 928 934 10.1016/j.ejca.2006.11.021 1:CAS:528:DC%2BD2sXisleitLs%3D 17267203 (Pubitemid 46366689)
29. H Lawnicka M Kowalewicz-Kulbat P Sicinska KH Altmann T Hofmann H Stepien 2009 Resorcylic acid lactone L-783, 277 inhibits the growth of the human adrenal cancer cell line H295R in vitro Int J Immunopathol Pharmacol 22 889 895 1:CAS:528:DC%2BC3cXjtFCqu7w%3D 20074452
30. JO Lee KW Lee CJ Kim YJ Kim HE Lee H Kim JH Kim SM Bang JS Kim JS Lee 2009 Metastatic adrenocortical carcinoma treated with sunitinib: a case report Jpn J Clin Oncol 39 183 185 10.1093/jjco/hyn146 19168875
31. R Libe A Fratticci J Bertherat 2007 Adrenocortical cancer: pathophysiology and clinical management Endocr Relat Cancer 14 13 28 10.1677/erc.1.01130 1:CAS:528:DC%2BD2sXhtlaksbjF 17395972 (Pubitemid 47521719)
32. S Mishra V Pertz B Zhang P Kaur H Shimada J Groffen Z Kazimierczuk LA Pinna N Heisterkamp 2007 Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2 Leukemia 21 178 180 10.1038/sj.leu.2404460 1:CAS:528:DC%2BD28XhtlSqurrP 17082777 (Pubitemid 44921853)
33. P O-charoenrat V Rusch SG Talbot I Sarkaria A Viale N Socci I Ngai P Rao B Singh 2004 Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung Clin Cancer Res 10 5792 5803 10.1158/1078-0432.CCR-03-0317 1:CAS:528: DC%2BD2cXntlyjs7k%3D 15355908 (Pubitemid 39180957)
34. MA Pagano F Meggio M Ruzzene M Andrzejewska Z Kazimierczuk LA Pinna 2004 2-Dimethylamino-4, 5, 6, 7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2 Biochem Biophys Res Commun 321 1040 1044 10.1016/j.bbrc.2004.07.067 1:CAS:528:DC%2BD2cXmt1OgtbY%3D 15358133 (Pubitemid 39044414)
35. A Patalano V Brancato F Mantero 2009 Adrenocortical cancer treatment Horm Res 71 Suppl 1 99 104 10.1159/000178049 1:CAS:528:DC%2BD1MXntVKjsQ%3D%3D 19153517
36. M Ruzzene LA Pinna 2010 Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 1804 499 504 1:CAS:528:DC%2BC3cXhs1ynu7k%3D 19665589
37. DC Seldin E Landesman-Bollag M Farago N Currier D Lou I Dominguez 2005 CK2 as a positive regulator of Wnt signalling and tumourigenesis Mol Cell Biochem 274 63 67 10.1007/s11010-005-3078-0 1:CAS:528:DC%2BD2MXmtVSgtLg%3D 16342409 (Pubitemid 41001501)
38. S Shin Y Lee W Kim H Ko H Choi K Kim 2005 Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8 EMBO J 24 3532 3542 10.1038/sj.emboj.7600827 1:CAS:528:DC%2BD2MXhtFaht7vE 16193064 (Pubitemid 41509361)
39. PS Soon KL McDonald BG Robinson SB Sidhu 2008 Molecular markers and the pathogenesis of adrenocortical cancer Oncologist 13 548 561 10.1634/ theoncologist.2007-0243 1:CAS:528:DC%2BD1cXotFait7s%3D 18515740 (Pubitemid 351872872)
40. M Tadjine A Lampron L Ouadi I Bourdeau 2008 Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas Clin Endocrinol (Oxf) 68 264 270 1:CAS:528:DC%2BD1cXjsFemt7k%3D
41. S Tawfic S Yu H Wang R Faust A Davis K Ahmed 2001 Protein kinase CK2 signal in neoplasia Histol Histopathol 16 573 582 1:CAS:528:DC%2BD3MXjt1Smtbc%3D 11332713
42. F Tissier C Cavard L Groussin K Perlemoine G Fumey AM Hagneré F René-Corail E Jullian C Gicquel X Bertagna MC Vacher-Lavenu C Perret J Bertherat 2005 Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors Cancer Res 65 7622 7627 1:CAS:528:DC%2BD2MXpslaitb4%3D 16140927
43. G Wang G Unger KA Ahmad JW Slaton K Ahmed 2005 Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy Mol Cell Biochem 274 77 84 10.1007/s11010-005-3077-1 1:CAS:528:DC%2BD2MXmtVSgtLs%3D 16342410 (Pubitemid 41001503)
44. G Wang KA Ahmad K Ahmed 2006 Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells Cancer Res 66 2242 2249 10.1158/0008-5472.CAN-05-2772 1:CAS:528:DC%2BD28XhsFals7g%3D 16489027
45. K Yamane TJ Kinsella 2005 Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine Clin Cancer Res 11 2355 2363 10.1158/1078-0432.CCR-04-1734 1:CAS:528:DC%2BD2MXisFaisro%3D 15788687 (Pubitemid 40490197)
46. CW Yde T Frogne AE Lykkesfeldt I Fichtner OG Issinger J Stenvang 2007 Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT Cancer Lett 256 229 237 10.1016/j.canlet.2007.06.010 1:CAS:528:DC%2BD2sXhtVOisLvJ 17629615 (Pubitemid 47418349)